An update on the use of biologic therapies in the management of uveitis in Behçet’s disease: a comprehensive review
Abstract ᅟ Behçet’s disease (BD) is a systemic vasculitis characterised by a relapsing remitting course, affecting multiple organ systems. In the eye, it is a cause of potentially blinding inflammation in the form of uveitis. Management of uveitis in BD often requires the use of systemic immunosuppr...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2017-07-01
|
| Series: | Orphanet Journal of Rare Diseases |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s13023-017-0681-6 |
| _version_ | 1819000705024786432 |
|---|---|
| author | Thomas W. McNally Erika M. Damato Philip I. Murray Alastair K. Denniston Robert J. Barry |
| author_facet | Thomas W. McNally Erika M. Damato Philip I. Murray Alastair K. Denniston Robert J. Barry |
| author_sort | Thomas W. McNally |
| collection | DOAJ |
| description | Abstract ᅟ Behçet’s disease (BD) is a systemic vasculitis characterised by a relapsing remitting course, affecting multiple organ systems. In the eye, it is a cause of potentially blinding inflammation in the form of uveitis. Management of uveitis in BD often requires the use of systemic immunosuppression, in order to reduce disease activity and prevent accumulation of irreversible damage. Whilst corticosteroids remain the mainstay of treatment, long-term use is limited by the development of adrenocorticotrophic side effects. There has therefore been significant interest in the use of corticosteroid-sparing immunosuppressive agents, and more recently, biologic therapies. Recent publications have demonstrated biologic therapy to have beneficial effects both on overall disease control, and quality of life for patients with BD. Widespread use of such agents is however limited, partly by the lack of high quality research evidence, and partly by the prohibitive cost of biologic treatments. In this review, we discuss the most recent research investigating the use of biologic therapy in uveitis due to BD, with consideration of health economics and quality of life outcomes. |
| first_indexed | 2024-12-20T22:37:33Z |
| format | Article |
| id | doaj.art-e5a0142a3a3b45d495900c2d885c470e |
| institution | Directory Open Access Journal |
| issn | 1750-1172 |
| language | English |
| last_indexed | 2024-12-20T22:37:33Z |
| publishDate | 2017-07-01 |
| publisher | BMC |
| record_format | Article |
| series | Orphanet Journal of Rare Diseases |
| spelling | doaj.art-e5a0142a3a3b45d495900c2d885c470e2022-12-21T19:24:34ZengBMCOrphanet Journal of Rare Diseases1750-11722017-07-0112111210.1186/s13023-017-0681-6An update on the use of biologic therapies in the management of uveitis in Behçet’s disease: a comprehensive reviewThomas W. McNally0Erika M. Damato1Philip I. Murray2Alastair K. Denniston3Robert J. Barry4University of Birmingham Medical School, University of BirminghamBehcet’s Centre of Excellence, City Hospital, Sandwell & West Birmingham Hospitals NHS TrustBehcet’s Centre of Excellence, City Hospital, Sandwell & West Birmingham Hospitals NHS TrustUniversity of Birmingham Academic Unit of Ophthalmology, Birmingham & Midland Eye Centre, City Hospital, Sandwell & West Birmingham Hospitals NHS TrustUniversity of Birmingham Academic Unit of Ophthalmology, Birmingham & Midland Eye Centre, City Hospital, Sandwell & West Birmingham Hospitals NHS TrustAbstract ᅟ Behçet’s disease (BD) is a systemic vasculitis characterised by a relapsing remitting course, affecting multiple organ systems. In the eye, it is a cause of potentially blinding inflammation in the form of uveitis. Management of uveitis in BD often requires the use of systemic immunosuppression, in order to reduce disease activity and prevent accumulation of irreversible damage. Whilst corticosteroids remain the mainstay of treatment, long-term use is limited by the development of adrenocorticotrophic side effects. There has therefore been significant interest in the use of corticosteroid-sparing immunosuppressive agents, and more recently, biologic therapies. Recent publications have demonstrated biologic therapy to have beneficial effects both on overall disease control, and quality of life for patients with BD. Widespread use of such agents is however limited, partly by the lack of high quality research evidence, and partly by the prohibitive cost of biologic treatments. In this review, we discuss the most recent research investigating the use of biologic therapy in uveitis due to BD, with consideration of health economics and quality of life outcomes.http://link.springer.com/article/10.1186/s13023-017-0681-6Behçet’s diseaseBiologic therapyHealth economicsImmunosuppressionQuality of lifeSteroid-sparing agents |
| spellingShingle | Thomas W. McNally Erika M. Damato Philip I. Murray Alastair K. Denniston Robert J. Barry An update on the use of biologic therapies in the management of uveitis in Behçet’s disease: a comprehensive review Orphanet Journal of Rare Diseases Behçet’s disease Biologic therapy Health economics Immunosuppression Quality of life Steroid-sparing agents |
| title | An update on the use of biologic therapies in the management of uveitis in Behçet’s disease: a comprehensive review |
| title_full | An update on the use of biologic therapies in the management of uveitis in Behçet’s disease: a comprehensive review |
| title_fullStr | An update on the use of biologic therapies in the management of uveitis in Behçet’s disease: a comprehensive review |
| title_full_unstemmed | An update on the use of biologic therapies in the management of uveitis in Behçet’s disease: a comprehensive review |
| title_short | An update on the use of biologic therapies in the management of uveitis in Behçet’s disease: a comprehensive review |
| title_sort | update on the use of biologic therapies in the management of uveitis in behcet s disease a comprehensive review |
| topic | Behçet’s disease Biologic therapy Health economics Immunosuppression Quality of life Steroid-sparing agents |
| url | http://link.springer.com/article/10.1186/s13023-017-0681-6 |
| work_keys_str_mv | AT thomaswmcnally anupdateontheuseofbiologictherapiesinthemanagementofuveitisinbehcetsdiseaseacomprehensivereview AT erikamdamato anupdateontheuseofbiologictherapiesinthemanagementofuveitisinbehcetsdiseaseacomprehensivereview AT philipimurray anupdateontheuseofbiologictherapiesinthemanagementofuveitisinbehcetsdiseaseacomprehensivereview AT alastairkdenniston anupdateontheuseofbiologictherapiesinthemanagementofuveitisinbehcetsdiseaseacomprehensivereview AT robertjbarry anupdateontheuseofbiologictherapiesinthemanagementofuveitisinbehcetsdiseaseacomprehensivereview AT thomaswmcnally updateontheuseofbiologictherapiesinthemanagementofuveitisinbehcetsdiseaseacomprehensivereview AT erikamdamato updateontheuseofbiologictherapiesinthemanagementofuveitisinbehcetsdiseaseacomprehensivereview AT philipimurray updateontheuseofbiologictherapiesinthemanagementofuveitisinbehcetsdiseaseacomprehensivereview AT alastairkdenniston updateontheuseofbiologictherapiesinthemanagementofuveitisinbehcetsdiseaseacomprehensivereview AT robertjbarry updateontheuseofbiologictherapiesinthemanagementofuveitisinbehcetsdiseaseacomprehensivereview |